Summary
Trimetrexate, a 2,4-diaminoquinazoline derivative, is a new antifol recently introduced into clinical trials. It differs from methotrexate principally in its transport (not carrier-mediated), and its intracellular retention (not polyglutamylated). Trimetrexate is active against tumors which are methotrexate-resistant on the basis of impaired transport, and has a broader range of antitumor activity in preclinical models. Animal studies predict toxicity principally to the central nervous system, gastrointestinal tract and bone marrow.
Similar content being viewed by others
References
Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA: The pharmacology and clinical use of methotrexate. New Engl J Med 309:1094–1104, 1983
Goldman ID: Membrane transport considerations in high-dose methotrexate regimens with leucovorin rescue. Cancer Treat Rep 65 (Suppl 1):13–18, 1981
Sirotnak FM, Chello PL, Piper JR, Montgomery JA: Growth inhibitory, transport, and biochemical properties of the -glutamyl and -aspartyl peptides of methotrexate in L1210 leukemia cells in vitro. Biochem Pharmacol 27: 1821–1825, 1978
Jolivet J, Chabner BA: Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells: selective retention and less dissociable binding of 4-NH2-10-CH3 PteGlu4 and 5 to dihydrofolate reductase. J Clin Invest (in press)
Krakower GR, Kamen BA: In situ methotrexate polyglutamate formation in rat tissues. J Pharmacol Exp Ther 227: 633–638, 1983
Elslager EF, Johnson JL, Werbel LM: Folate antagonists 20. Synthesis, antitumor and antimalarial properties of trimetrexate and related 6-[[(phenyl)amin]-methyl]-2,4-quinazolinediamine. J Med Chem (in press), 1983
Bertino JR, Sawicki WL, Moroson BA, Cashmore AR, Elslager EF: 2,4-Diamino-5-methyl-6-[3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ), a potent nonclassical folate antagonist inhibitor. I. Effect on dihydrofolate reductase and growth of rodent tumors in vitro and in vivo. Biochem Pharmacol 28:1983–1987, 1979
Broome MG, Johnson RK, Wodinsky I: Biochemical and biological characterization of two new antifols, NSC 127755 and TMQ, in comparison with methotrexate. (Abstract) Proc Am Assoc Cancer Res 21:309, 1980
Broome MG, Johnson RK, Evans SF, Wodinsky I: Leucovorin reversal studies with TMQ and a triazinate antifol in comparison with methotrexate. (Abstract) Proc Am Assoc Cancer Res 23:178, 1982
Duch DS, Edelstein MP, Nichol CA: Inhibition of histamine-metabolizing enzymes and elevation of histamine levels in tissues by lipid-soluble anticancer folate antagonists. Mol Pharmacol 18 (1): 100–104, 1980
Bertino JR, Sawicki WL: Potent inhibitory activity of trimethoxyquine (TMQ), a “nonclassical” 2,4 diaminoquinazoline, on mammalian DNA synthesis. (Abstract) Proc Am Assoc Cancer Res 18:168, 1977
Kamen BA, Eibl B, Cashmore AR, Whyte WL, Moroson BA, Bertino JR: Efficacy and transport of a new lipid soluble antifol, 2,4-diamino-5-methyl-6-[(3,4,5,-trimethoxyanilino)methyl]quinazoline (TMQ; JB11) in methotrexate resistent cells. (Abstract) Proc Am Soc Cancer Res 22:26, 1981
Scanlon K, Ohnuma T, Lo RJ, Nichol CA, Waxman S, Greenspan EM, Holland JF: Effects of 2,4-diamino-6-(2,5-dimethoxybenzyl)-5-methylpyrido(2,3-D)pyrimidine (BW301U) on methotexate (MTX)-resistant human acute lymphoblastic leukemia (ALL) cell lines. (Abstract) Proc Am Soc Clin Oncol 23:12, 1982
Diddens H, Niethammer D, Jackson RC: Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB 3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 43: 5286–5292, 1983
Kamen BA, Eibl B, Cashmore A, Bertino J: Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-(3,4, 5-trimethoxyanilinomethyl) quinazoline) a non-classical antifolate in MTX-resistant leukemia cells in vitro. Biochem Pharmacol, (in press)
Weir EC, Cashmore AR, Dreyer RN, Graham MS, Hsiao N, Moroson BA, Sawicki WL, Bertino JR: Pharmacology and toxicity of potent “nonclassical” 2,4-diaminoquinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res 42:1696–1702, 1982
Heusner J, McCormack J: Enzymatic Assays for 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline, a promising new “nonclassical” antifolate. J Pharm Sci 70:827–828, 1981
NCI Clinical Brochure for trimetrexate glucuronate, November 1983
Data on file, Warner-Lambert/Parke-Davis Pharmaceutical Research Division, November 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Dwyer, P.J., Shoemaker, D.D., Plowman, J. et al. Trimetrexate: a new antifol entering clinical trials. Invest New Drugs 3, 71–75 (1985). https://doi.org/10.1007/BF00176828
Issue Date:
DOI: https://doi.org/10.1007/BF00176828